INHIBITION OF INTERLEUKIN-2 RECEPTOR EXPRESSION IN NORMAL HUMAN T-CELLS BY CYCLOSPORINE - DEMONSTRATION AT THE MESSENGER-RNA, PROTEIN, AND FUNCTIONAL LEVELS

被引:24
作者
LI, BG
SEHAJPAL, PK
SUBRAMANIAM, A
JOSEPH, A
STENZEL, KH
SUTHANTHIRAN, M
机构
[1] CORNELL UNIV,MED CTR,COLL MED,ROGOSIN INST,CTR IMMUNOGENET & TRANSPLANTAT,NEW YORK,NY 10021
[2] CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021
[3] CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021
关键词
D O I
10.1097/00007890-199201000-00030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In view of the importance of the IL-2 receptors in the expression of antiallograft immunity and the currently existing controversy regarding the effect of CsA on the induction of IL-2 receptors, we explored the effect of cyclosporine on the induction of interleukin-2 receptor alpha and beta in normal human T cells. The effect of CsA on the induction of IL-2 receptors was examined at the levels of mRNA expression (with the aid of the polymerase chain reaction), protein (by SDS-PAGE analysis of chemically crosslinked I-125-IL-2 membrane protein complexes and by FACS), and function (by Scatchard analysis of I-125-IL-2 binding to T cells). The T cells were signaled with sn-1,2-dioctanoylglycerol and ionomycin or with crosslinked anti-CD3 and anti-CD2 mAbs. Our experimental design revealed that (A) CsA inhibits the induction of IL-2 receptor alpha and beta in normal human T cells, (B) the inhibitory activity is realized by a direct effect on T cells, and (C) the inhibitory activity is detectable at the pretranslational level--CsA significantly reduced the induction of mRNA encoding IL-2 receptor alpha and IL-2 receptor beta. These observations together persuasively demonstrate the ability of CsA to interrupt the emergence of IL-2 receptors on the surface of normal human T cells.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 14 条
[1]   ANALYSIS OF CYTOKINE MESSENGER-RNA AND DNA - DETECTION AND QUANTITATION BY COMPETITIVE POLYMERASE CHAIN-REACTION [J].
GILLILAND, G ;
PERRIN, S ;
BLANCHARD, K ;
BUNN, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2725-2729
[2]  
KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
[3]   A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL-ANTIBODY IN HUMAN RENAL-TRANSPLANTATION [J].
KIRKMAN, RL ;
SHAPIRO, ME ;
CARPENTER, CB ;
MCKAY, DB ;
MILFORD, EL ;
RAMOS, EL ;
TILNEY, NL ;
WALDMANN, TA ;
ZIMMERMAN, CE ;
STROM, TB .
TRANSPLANTATION, 1991, 51 (01) :107-113
[4]   WOUND MACROPHAGES EXPRESS TGF-ALPHA AND OTHER GROWTH-FACTORS INVIVO - ANALYSIS BY MESSENGER-RNA PHENOTYPING [J].
RAPPOLEE, DA ;
MARK, D ;
BANDA, MJ ;
WERB, Z .
SCIENCE, 1988, 241 (4866) :708-712
[5]   DEMONSTRATION OF A DIRECT INHIBITORY EFFECT OF CYCLOSPORINE ON NORMAL HUMAN T-CELLS WITH 2 NOVEL MODELS OF T-CELL ACTIVATION AS PROBES [J].
SEHAJPAL, P ;
SUBRAMANIAM, A ;
MURTHI, VK ;
SHARMA, VK ;
SUTHANTHIRAN, M .
CELLULAR IMMUNOLOGY, 1989, 120 (01) :195-204
[6]   THE MOLECULAR-BASIS FOR THE SYNERGISM BETWEEN THE CD3/ALPHA-BETA T-CELL RECEPTOR AND THE CD2 ANTIGEN-DERIVED SIGNALS IN PROMOTING T-CELL PROLIFERATION [J].
SEHAJPAL, PK ;
LI, B ;
ZANKER, B ;
MURTHI, VK ;
SUBRAMANIAM, A ;
SHARMA, VK ;
ESTIN, D ;
SKOLNIK, EY ;
WIEDER, KJ ;
WALZ, G ;
FOTINO, M ;
STENZEL, KH ;
STROM, TB ;
SUTHANTHIRAN, M .
TRANSPLANTATION, 1991, 51 (02) :468-474
[7]  
SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397
[8]   INTERLEUKIN-2 - INCEPTION, IMPACT, AND IMPLICATIONS [J].
SMITH, KA .
SCIENCE, 1988, 240 (4856) :1169-1176
[9]   RANDOMIZED CONTROLLED TRIAL OF A MONOCLONAL-ANTIBODY AGAINST THE INTERLEUKIN-2 RECEPTOR (33B3.1) AS COMPARED WITH RABBIT ANTITHYMOCYTE GLOBULIN FOR PROPHYLAXIS AGAINST REJECTION OF RENAL-ALLOGRAFTS [J].
SOULILLOU, JP ;
CANTAROVICH, D ;
LEMAUFF, B ;
GIRAL, M ;
ROBILLARD, N ;
HOURMANT, M ;
HIRN, M ;
JACQUES, Y .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (17) :1175-1182
[10]   ACTIVATION OF HUMAN T-CELLS WITH THE PHYSIOLOGICAL REGULATOR OF PROTEIN KINASE-C [J].
SUBRAMANIAM, A ;
SEHAJPAL, P ;
MURTHI, VK ;
STENZEL, KH ;
SUTHANTHIRAN, M .
CELLULAR IMMUNOLOGY, 1988, 116 (02) :439-449